Facing the Challenges in Vaccine Upstream Bioprocessing - 2

Continuous Growth
Fibra-Cel® disks-3-D growth matrix for perfusion and continuous processes
Suspend your disbelief: The three-dimensional Fibra-Cel matrix entraps
anchorage dependent and suspension cells-for optimized growth conditions
and increased yields.

> Less susceptible to shear forces, clogging, and fouling
> Ideal for secreted product and vaccine production
> Suitable for GMP production
> For use in autoclavable, sterilize-in-place or BioBLU® Single-Use Vessels

www.eppendorf.com/Fibra-Cel
Fibra-Cel® is a registered trademark owned by Imerys Minerals California, Inc., USA and licensed to Eppendorf, Inc., USA. Eppendorf ®, the Eppendorf Brand Design and BioBLU® are registered trademarks of Eppendorf AG, Germany. All rights reserved, including graphics and images. Copyright © 2018 by Eppendorf AG.



http://www.eppendorf.com/Fibra-Cel

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com